Therapeutic use of low-dose corticosteroids to treat neutropenia resulting from crizotinib administration in a patient with anaplastic lymphoma kinase gene translocation-positive lung cancer

7Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

Background. Neutropenia has been reported to be an adverse effect of crizotinib treatment: however, its pathogenesis remains unknown. Case. A 46-year-old male who developed cardiac tamponade was diagnosed with lung adenocarcinoma associated with pericarditis carcinomatosa and brain metastasis. Following the administration of pericardial sclerotherapy and whole-brain radiotherapy, he received two cycles of carboplatin plus pemetrexed, although the disease progressed. Thereafter, anaplastic lymphoma kinase (ALK) gene translocation was identified in metastatic lymph nodes on fluorescent in situ hybridization. Therefore, treatment with 500 mg of crizotinib daily was initiated. Although the therapy was effective, grade 3 neutropenia was noted two weeks after the start of treatment. The neutropenia persisted despite the discontinuation of crizotinib, and 10 mg of prednisolone was administered daily as treatment. The crizotinib therapy was restarted after the administration of prednisolone, and the patient exhibited a good response for the next six months. Conclusions. We herein report the case of a patient with ALK-positive lung cancer successfully treated with crizotinib in whom neutropenia was treated with prednisolone. © 2014 The Japan Lung Cancer Society.

References Powered by Scopus

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

4755Citations
N/AReaders
Get full text

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer

3110Citations
N/AReaders
Get full text

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: Updated results from a phase 1 study

1133Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC

27Citations
N/AReaders
Get full text

A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK<sup>+</sup> lymphomas

11Citations
N/AReaders
Get full text

Successful Management of Crizotinib-Induced Neutropenia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Case Report

6Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Toyota, Y., Sakugawa, M., Bessho, A., Horiuchi, T., Hosokawa, S., & Watanabe, Y. (2014). Therapeutic use of low-dose corticosteroids to treat neutropenia resulting from crizotinib administration in a patient with anaplastic lymphoma kinase gene translocation-positive lung cancer. Japanese Journal of Lung Cancer, 54(2), 78–83. https://doi.org/10.2482/haigan.54.78

Readers' Seniority

Tooltip

Researcher 1

100%

Readers' Discipline

Tooltip

Medicine and Dentistry 1

50%

Biochemistry, Genetics and Molecular Bi... 1

50%

Save time finding and organizing research with Mendeley

Sign up for free